SunTrust Banks Comments on Pfizer, Inc.’s Q4 2017 Earnings (PFE)
Pfizer, Inc. (NYSE:PFE) – Equities research analysts at SunTrust Banks lifted their Q4 2017 earnings per share (EPS) estimates for shares of Pfizer in a report issued on Tuesday. SunTrust Banks analyst J. Boris now anticipates that the biopharmaceutical company will post earnings of $0.60 per share for the quarter, up from their previous estimate of $0.59. SunTrust Banks also issued estimates for Pfizer’s FY2020 earnings at $2.78 EPS.
Several other analysts have also recently issued reports on PFE. Berenberg Bank restated a “hold” rating and set a $36.00 target price (down from $39.00) on shares of Pfizer in a research report on Tuesday, August 15th. BMO Capital Markets restated a “buy” rating and set a $37.00 target price on shares of Pfizer in a research report on Thursday. BidaskClub upgraded shares of Pfizer from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 5th. Vetr cut shares of Pfizer from a “buy” rating to a “hold” rating and set a $35.71 target price on the stock. in a research report on Wednesday. Finally, Cowen and Company set a $43.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research report on Monday, August 14th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $37.72.
TRADEMARK VIOLATION WARNING: This article was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/09/15/suntrust-banks-comments-on-pfizer-inc-s-q4-2017-earnings-pfe.html.
Pfizer (PFE) opened at 35.74 on Friday. The stock has a market cap of $212.56 billion, a P/E ratio of 26.14 and a beta of 1.00. The stock has a 50 day moving average price of $33.58 and a 200 day moving average price of $33.52. Pfizer has a 12-month low of $29.83 and a 12-month high of $35.84.
Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The business had revenue of $12.90 billion for the quarter, compared to the consensus estimate of $13.08 billion. During the same quarter last year, the business posted $0.64 earnings per share. The company’s revenue for the quarter was down 1.9% on a year-over-year basis.
A number of institutional investors and hedge funds have recently made changes to their positions in PFE. Asset Planning Services Ltd. boosted its stake in Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock valued at $101,000 after acquiring an additional 137 shares in the last quarter. Shine Investment Advisory Services Inc. acquired a new stake in Pfizer in the second quarter valued at approximately $102,000. Mckinley Capital Management LLC Delaware acquired a new stake in Pfizer in the second quarter valued at approximately $103,000. D. Scott Neal Inc. boosted its stake in Pfizer by 19.3% in the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 504 shares in the last quarter. Finally, Orrstown Financial Services Inc. boosted its stake in Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock valued at $112,000 after acquiring an additional 612 shares in the last quarter. Institutional investors own 69.09% of the company’s stock.
In other Pfizer news, insider Alexander R. Mackenzie sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $33.50, for a total value of $502,500.00. Following the completion of the sale, the insider now directly owns 151,474 shares in the company, valued at $5,074,379. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Sally Susman sold 38,230 shares of the firm’s stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the completion of the sale, the insider now owns 145,649 shares of the company’s stock, valued at $5,097,715. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 464,521 shares of company stock worth $15,813,961. Insiders own 0.06% of the company’s stock.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 1st. Stockholders of record on Friday, August 4th were paid a dividend of $0.32 per share. The ex-dividend date was Wednesday, August 2nd. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.58%. Pfizer’s dividend payout ratio is presently 94.12%.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.